EUROEYES (01846) completes acquisition of Dutch ophthalmology company.

EuroEyes (01846) announced that the shareholders' approval of the purchase and sale agreement and the transactions planned thereunder, as well as the subscription agreement and the transactions planned thereunder, have been obtained at the special general meeting of shareholders. All the conditions precedent under the purchase and sale agreement and the subscription agreement have been satisfied, and the completion of the acquisition and subscription was confirmed on July 22, 2026 (after the trading period). The total consideration determined by the formula disclosed in the circular is 131 million euros, including (i) a fixed equity consideration of 131.8 million euros; in addition to (ii) a lock-box compensation of 14.2372 million euros; minus (iii) a leakage amount of 14.6531 million euros. According to the structure of the acquisition disclosed in the circular, the consideration is borne by the Company and Manco amounting to 118 million euros and 12.725 million euros, respectively. The consideration is funded through the funding sources disclosed in the circular, and payment will be strictly made in accordance with the disclosed order and priority. Upon completion of the subscription, the total investment made by the Company in EuroEyes Netherlands is 118.6 million euros, and the total issue price for the participants to subscribe for shares is 12.725 million euros. Further investment includes a reinvestment amount of 2.075 million euros by the surgeons, and a reinvestment amount of 10.65 million euros by the management. Nine surgeons have exercised the reinvestment opportunity, totaling 2.075 million euros. Following the completion of the subscription, the issued capital of EuroEyes Netherlands is owned by the Company and Manco by approximately 90.31% and 9.69%, respectively. After the completion of the subscription, the Company, Manco, EuroEyes Netherlands, STAK, and the management have entered into a shareholders' agreement to regulate their respective rights and obligations, and to grant call and put options.